PropertyValue
?:abstract
  • COVID-19 pandemic is an emergent cardiovascular risk factor and a major cause of mortality worldwide. Thromboembolism is highly suspected as a leading cause of death in these patients through vascular inflammation caused by SARS COV2. Until now there is no real treatment of COVID-19 and many proposed drugs are under clinical trials. Considering the high incidence of thromboembolic events in critically ill patients with COVID-19, prevention of this disorder should be essential in order to reduce mortality in these patients.
?:creator
?:doi
  • 10.11604/pamj.2020.35.2.22947
?:doi
?:journal
  • Pan_Afr_Med_J
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/9448437c97cdd9c7123528214c11e35f24908a2a.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7266478.xml.json
?:pmcid
?:pmid
?:pmid
  • 32528622.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • COVID-19 pandemic: do we need systematic screening of patients with cardiovascular risk factors in Low and Middle-Income Countries (LMICs) for preventing death?
?:type
?:year
  • 2020-04-29

Metadata

Anon_0  
expand all